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Cross-validationPredicting Anatomical Therapeutic Chemical (ATC) code of drugs is of vital importance for drug classifi-
cation and repositioning. Discovering new association information related to drugs and ATC codes is still
difficult for this topic. We propose a novel method named drug–domain hybrid (dD-Hybrid) incorporat-
ing drug–domain interaction network information into prediction models to predict drug’s ATC codes. It
is based on the assumption that drugs interacting with the same domain tend to share therapeutic
effects. The results demonstrated dD-Hybrid has comparable performance to other methods on the gold
standard dataset. Further, several new predicted drug-ATC pairs have been verified by experiments,
which offer a novel way to utilize drugs for new purposes effectively.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Despite the increase of financial investments in pharmaceutical
R&D, the number of newly approved drugs has greatly reduced in
the past decade [1]. Finding new uses for approved drugs has
become a major issue in the pharmaceutical industry. This practice,
usually referred to as drug classification and repositioning, is
highly concerned due to its potential to speed up the process of
drug development. The Anatomical Therapeutic Chemical (ATC)
classification system, recommended by the World Health Organi-
zation (WHO), is one way to solve this issue. In the ATC classifica-
tion system, drugs are divided into 14 main groups by their first
level according to their anatomical annotation. The system has five
levels and each of them represents one biological category. There
are only a small part of drugs with their corresponding ATC codes.
Even in some famous databases like KEGG BRITE [2] and DrugBank
[3], many drugs still don’t have their ATC codes. Therefore, it is
urgent to discover the suitable ATC codes for current drugs, which
may provide new clues for drug reposition and application. Due to
the high costs of experiments, some effective computational
approaches have been proposed to predict suitable ATC codes for
drugs.Wu et al. was the first attempt to discover the relationship
among ATC classes and correlated ATC classed by their drug set
similarity [4]. These relationships were assigned for approved
drugs and make reasonable predictions. However, it is not based
on a machine-learning framework. Gurulingappa et al. developed
an approach based on a combination of information extraction
(IE) and machine learning techniques for concept-based drug class
prediction [5]. The method employed an IE-based framework to
extract terms from free text as features within a machine learning
framework to predict ATC class labels for unclassified drugs.
Though this concept-based method provided a new possibility to
categorize the existing drugs, it has some limitation about the gen-
eralization of the method. Recently, much effort has been devoted
to the discovery of important biological similarity feature related
to drugs and ATC codes. Most of these methods rely on the success-
ful idea of utilizing more structural similarity of chemical com-
pounds and similarity of targets. Dunkel et al. predicted drug’s
ATC codes by the structural similarity of chemical compounds. It
is based on the assumption that compounds with similar physico-
chemical properties show similar biological activity [6]. It also pro-
vided a web-server for prognoses about the medical indication area
of novel compounds and to find new leads for known targets.
Nickel et al. updated the SuperPred web server through increasing
known compound–target interactions and taking 3D similarity as
well as the concordance of physic-chemical properties into account
[39]. Chen et al. developed a method to predict drug’s ATC code by
integrating the information of chemical–chemical interactions and
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information into feature as a hybrid method [12]. Wang et al. pro-
posed a network-based method NetPredATC by integrating chem-
ical structures and target proteins. It is based on the idea that drugs
with common protein targets often have similar therapeutic func-
tion [8,9]. He also constructed a gold-standard positive dataset
from drug’s ATC code annotation databases [10]. Napolitano et al.
integrated gene expression, chemical structure and target informa-
tion as drug similarity to predict drug’s ATC code [11].
Despite the success obtained by the methods mentioned above,
there is still much room for improvement in the prediction. Inte-
grating useful biological information about drugs and ATC codes
is critical to the problem of drug’s ATC code prediction. Recently,
it has been found that protein–protein interactions are dominated
by domain–domain interactions [13,14]. Besides, the method Net-
PredATC proposed by Wang et al. integrated target protein infor-
mation into drug similarity. Since the fact that domains are
connected to target protein, we suspect that domain information
may become a supplement to target protein information in drug’s
ATC code prediction even though the drugs do not physically bind
to protein domains. Most recently, it is reported that drugs inter-
acting with the same domain (structural and functional building
blocks) tend to share therapeutic effects [15,16], which confirms
our hypotheses to some extent.
As demonstrated by a series of recent publications [40–44] and
according to Chou’s 5-step rule [45], to establish a useful
sequence-based algorithm, we should consider the following five
guidelines: (a) construct or select a valid benchmark dataset to train
and test the predictor; (b) formulate the biological sequence sam-
pleswith a validmathematical expression that can truly reflect their
inherent relationwith the target to bepredicted; (c) develop auseful
algorithm (or server) to operate the prediction; (d) take cross-
validations to evaluate the accuracy of the predictor; (e) build a
user-friendly web-server that is accessible to the user. According
to these guidelines, we propose a new drug–domain hybrid (dD-
Hybrid) method to predict the unlabeled drug ATC-code pairs in
the drug-ATC network by integrating drug–domain network. Our
method is based on the hypothesis that a domain is connected with
a group of drugs sharing the same ATC code [17]. Firstly, we identify
drug–domain interaction through investigating the domain compo-
nents of proteins bound by the drugs in the dataset. Secondly, new
drug-ATC code pairs are predicted by integrating calculated drug–
domain scores obtained by drug–domain interaction with the
drug-ATCnetwork. Benchmarkingwith knowndrug-ATC code pairs,
the dD-Hybrid method demonstrates its comparative advantage
with existingmethods that utilize target protein informationon four
benchmark datasets including G-protein coupled receptors (GPCR),
ion channel (IC), enzymes, and nuclear receptors, which verifies the
initial hypothesis and effectiveness of the method.2. Materials and methods
2.1. Constructing drug-ATC networks
We use the dataset from Wang et al. [10] as the gold standard
dataset. The data can be obtained in the Supplementary material.
The drug and ATC-annotation information is extracted from KEGG
BRITE [19] and DrugBank [3] database. For a given drug and ATC
code pair, the problem is to predict whether the drug has the
ATC code or not. To simplify the problem, we treat this problem
as a binary-classification problem. We construct a bipartite graph
by using the drugs and ATC codes annotation. The nodes represent
drugs and ATC codes. An edge exists between the drug and ATC
code if the drug has the ATC code. Our aim is to predict the missing
edges in the drug and ATC network.2.2. Collecting similarity and domain information
2.2.1. Drug similarity data
To calculate the chemical structures of drugs involved in the
dataset, we used a fingerprint consisting of 881 chemical substruc-
tures defined in the PubChem database [20]. The chemical finger-
print can also be calculated by a software—PaDel-Descriptor [21].
Each drug was represented by an 881 dimensional binary vector
whose elements for the absence or presence of each PubChem sub-
structure by 0 or 1, respectively. Then Tanimoto scores (Ts) [22] of
each two drugs can be calculated by corresponding fingerprints.
We use the Ts value of the fingerprints Simdrug represents the drug
structure similarity.2.2.2. ATC similarity data
The ATC similarity data consists of two aspects: ATC hierarchi-
cal structure similarity and ATC evaluating score (Es) similarity.
The ATC hierarchical structure similarity SATC is calculated by a
probabilistic model [23] and we use the data from [10].
Introducing Es similarity of ATC pairs is based on the assump-
tion that if two ATC codes contain common or similar drugs, there
might be some connections between them [4]. The similarity-
based theory has been applied to the study of relationships
between proteins, where proteins are relied on the basis of their
legend set similarity [24]. We regard each ATC code as a drug
set, the similarity of two ATC codes can be represented as the sim-
ilarity of corresponding drug sets. Since the chemical fingerprint
has been used as one kind of drug similarity, the Es value of two
ATC codes is introduced to represent the ATC similarity. Es value
is calculated as the sum of the Tanimoto score of all drug pairs in
each two drug sets, as follows:
Es ¼
Xm
i¼1
Xn
j¼1
Tsij ð1Þ
ATC evaluating score similarity SEs is calculated through the Es
value of each ATC pair. To ensure the reliability of cross-
validation result, we get rid of the related drug and ATC code infor-
mation in the testing set. To get reasonable result, we find the best
combination by using the maximum value SimATC of SATC and SEs as
the final ATC similarity, as follows:
SimATC ¼maxðSATC ; SEsÞ ð2Þ2.2.3. Construct drug–domain interaction network
First, we extract the drug–target interaction from DrugBank [3]
according to drugs with KEGG [2] compound identifier. High-
confidence drug–target interactions from MATADOR [25] are
added to our data to get a comprehensive set of drug–target inter-
actions. According to the interactions, we find the proteins inter-
acted with the drugs in the dataset from Uniprot [26] database.
Here we consider two complementary perspectives on protein
domains: the structural perspective provided by CATH [27] and
the function-oriented perspective offered by PFAM [28]. Therefore,
we extract CATH and PFAM domain information binding to pro-
teins from Gene3D [29] and BioMart [30] database, respectively.
We construct a drug–domain network through drug–domain inter-
action (Fig. 1). Each drug is connected to some Cath and Pfam
domains.
Each number in the blanket denotes number of edges that Drug
i associates with Cath or Pfam j in the drug–domain network. Since
we have two types of domain, we construct two networks: drug-
Cath network and drug-Pfam network. In case these two types of
domain information have different impact on the results, we calcu-
late two types of drug–domain score separately. So the calculation
Fig. 1. Drug–domain interaction network.
Fig. 2. The flow diagram of the dD-Hybrid method. Simdrug: drug–drug similarity.
SimATC: ATC–ATC similarity.
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Cath and Pfam.
Here a scoring scheme based on the information of a drug con-
nects to a domain [17]. Each drug–domain pair score s(dD) is calcu-
lated as follows:
Pðd;DÞ ¼ pðdÞ  pðDÞ ¼ ndP
d
 
 nDP
D
 
ð3Þ
IðdDÞ ¼ log2Pðd;DÞ ð4Þ
SðdDÞ ¼ NðdDÞ  IðdDÞ ð5Þ
I(dD) is the self-information of each drug–domain pair. P(d,D) is the
probability of drug d interacts with domain D. nd and nD is the
times of drugs and domains appeared in the dataset, respectively.
N(dD) is the times of dD pair appeared in the drug–domain network.
In this way, we can get a drug–domain score matrix. We find
there exist many zeros in the matrix, which implies it is a sparse
matrix. So we transform zero in the matrix into a value between
1 and 1 through the process of mean normalization. If x denotes
each column vector, the process of mean normalization is shown as
follows:
X ¼ x xmean
s
ð6Þ
xmean denotes the mean value of x vector and s denotes the standard
deviation of x vector. After that, the new drug–domain score matrix
is added to former integrated features as new drug features.
2.3. Combining measures to classification features
In the machine learning framework, each drug and ATC-code
pair is a sample. If one drug interacts with an ATC code, we treat
one drug and ATC-code pair as a positive sample. Else, negative
sample. To make a balance between the gold – standard positive
and negative samples, we select all the positive samples in the
dataset and take a random selection among unlabeled samples.
We choose almost the same size of positive samples from unla-
beled samples as negative samples.
After selecting the samples we use, we use a measure to inte-
grate features. For each two drug and ATC-code pairs daTa and db-
Tb, we calculate their similarity as follows:
SimðdaTa; dbTbÞ ¼ Simdrugðda; dbÞ  SimATCðTa; TbÞ ð7Þ
where Simdrug represents drug–drug similarity and SimATC repre-
sents ATC–ATC similarity. The method relies on the theory that
two drug-ATC pairs are more likely to have similar function if the
two drugs and two ATC-codes are both similar [10].The key of our method is the drug–domain score combined into
the feature. In the drug–domain score matrix, each row in it repre-
sents a new drug feature. We add each new drug feature in the
drug–domain score matrix to the same row in sim(daTa,dbTb). We
use three combinations of drug–domain score: drug-Cath score,
drug-Pfam score, and both of them. If we use both of them, we
should add each new drug feature in the drug-Cath score matrix
and drug-Pfam score matrix to the same row in sim(daTa,dbTb).
For a given drug and an ATC code, the aim of our problem is to
predict whether the drug has the ATC code. Each drug and ATC-
code pair has its own label, 1 or 0. So the problem can be treated
as a binary-classification problem. For the purpose of supervised
learning and accurate prediction, a popular machine learning algo-
rithm support vector machine (SVM) is applied. The SVM algorithm
is widely used in binary-classification problem [31]. Here we train
the SVM-based predictor by using LibSVM [32]. The flow diagram of
the method is shown in Fig. 2.
In statistical prediction area, three cross-validation methods are
often used to examine the effectiveness of a predictor in practical
application: independent dataset test, subsampling test, and jack-
knife test. However, of the three test methods, the jackknife test
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for a benchmark dataset as explained in [45] and demonstrated by
Eqs. (28)–(30) therein. Accordingly, the jackknife test has been
widely used and recognized by researchers to examine the quality
of various predictors (see, e.g., [46–52]). However, to reduce the
computational time, here we adopted the 10-fold cross-
validation in this work as done by many researchers with SVM as
the prediction engine. The whole samples are spilt into 10 subsets
with equal size. In every fold, we choose one subset in turn as test-
ing set. Then the remaining nine subsets are used as training set.
We train the model on the training set and validate the result on
the testing set. The process has been repeated for 10 times.3. Results
3.1. Topological analysis of drug–domain network
We use IC-Pfam information to construct an IC-PFAM network
using Cytoscape (version 2.8.2) [33]. There are 391 nodes (181
drugs and 210 pfams) and 1065 edges in the whole network. 16
drugs in all 197 drugs interacting with ICs don’t have interactions
with domains. By reason of large amounts of nodes and edges, we
choose some PFAM domains with a large degree and drugs con-
nected to them into a sub-network (Fig. 3). Green diamonds repre-
sent PFAM domains with a degree of larger than 20 and red dotsFig. 3. Part of IC-pfam nPfamrk constructed by IC-pfam information. Green diamonds rep
connected to these pfam domains. Edge between a drug and a domain denotes the inte
legend, the reader is referred to the web version of this article.)represent drugs connected to these PFAM domains. Edge between
a drug and a PFAM domain denotes their interaction.
Furthermore, we calculate the percentage of Pfam nodes with
different degrees (Table 1). The percentage of Pfam nodes with
only one degree in all the nodes is 42.9%. Nodes with a degree of
smaller than 20 take 95.7% of all the nodes. It indicates that only
few nodes have large amounts of connections, and most nodes
have a small number of connections in the network. In the IC-
PFAM network, only the degree of PF00001 and PF00520 is larger
than 50. Researchers have shown that these high-connected nodes
are the hub of the whole network, which means they play a key
role in the properties of the network [34]. Therefore, it may be
an instruction to our future work due to the idea that domains,
connecting with most drugs have an important influence on the
prediction results.
3.2. Data integration improves prediction
We use the integrated data as features in the drug-ATC code
prediction problem. We compare the performance of adding three
types of domain information. ATC is a multi-label system [58]. For
the multi-label systems, a completely different set of metrics as
defined in [59] is more and more frequently used in system biology
[60–65] and system medicine [57,58]. In our work, to make an
intuitive and well understood comparison between four
conditions, the result is visualized by ROC curve [35] and PRresent PFAM domains with a degree of larger than 20 and red dots represent drugs
raction between them. (For interpretation of the references to color in this figure
Table 1
The distribution of PFAM nodes with different degrees. k denotes the degree of PFAM
nodes.
Maximum degree The percentage of PFAM nodes with different degrees (%)
k = 1 1 < k 6 5 5 < k 6 20 20 < k 6 50 k > 50
79 42.9 37.1 15.7 3.3 1.0
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result by calculating Sensitivity (Sn), Specificity (Sp), F-measure,
MCC, AUC (area under the ROC curve), AUPR (area under the PR
curve) and accuracy (ACC) (Table 2).
Chemfingerprint is the method using chemical fingerprint
similarity, Chemfingerprint_cath, chemfingerprint_pfam,Fig. 4. ROC and PR curves for the methods using d
Table 2
Performance comparison of four methods to predict drug’s ATC-codes. The best results ar
Dataset Methods Sn Sp
Enzymes Chemfingerprint 0.781 0.768
Chemfingerprint_cath 0.903 0.805
Chemfingerprint_pfam 0.890 0.823
Chemfingerprint_cath_pfam 0.894 0.825
ICs Chemfingerprint 0.701 0.747
Chemfingerprint_cath 0.815 0.711
Chemfingerprint_pfam 0.817 0.799
Chemfingerprint_cath_pfam 0.806 0.794
GPCRs Chemfingerprint 0.757 0.787
Chemfingerprint_cath 0.867 0.807
Chemfingerprint_pfam 0.863 0.800
Chemfingerprint_cath_pfam 0.867 0.797
NRs Chemfingerprint 0.779 0.768
Chemfingerprint_cath 0.865 0.842
Chemfingerprint_pfam 0.886 0.811
Chemfingerprint_cath_pfam 0.886 0.768chemfingerprint_cath_pfam are the methods combing drug-Cath
score, drug-Pfam score and both, respectively. We find our method
has a better result on four datasets after combing domain informa-
tion into former features (Table 2). It also implies different types of
domain may have different impact on drugs interacting with dif-
ferent target families.3.3. Comparison with other methods
As we mentioned above, NetPredATC is a learning method that
used to predict drug’s ATC code [10]. In their work, drug similarity
based on target proteins is integrated into drug chemical similar-
ity. Further, we compare the performance with this classical
method. Due to the fact there are more unlabeled samples than
positive samples, it is more meaningful to compare the value ofifferent datasets to predict drug’s ATC codes.
e highlighted in bold.
F-measure MCC AUC AUPR ACC
0.781 0.563 0.839 0.823 0.781
0.861 0.724 0.894 0.888 0.861
0.861 0.715 0.898 0.892 0.857
0.864 0.721 0.898 0.892 0.860
0.718 0.449 0.813 0.849 0.726
0.815 0.630 0.883 0.884 0.815
0.817 0.633 0.892 0.892 0.817
0.806 0.612 0.863 0.867 0.806
0.768 0.544 0.850 0.873 0.772
0.841 0.675 0.882 0.883 0.837
0.837 0.665 0.880 0.882 0.832
0.837 0.665 0.878 0.881 0.832
0.775 0.547 0.864 0.865 0.774
0.878 0.749 0.890 0.893 0.874
0.876 0.742 0.890 0.889 0.868
0.859 0.704 0.884 0.883 0.858
F.-S. Chen, Z.-R. Jiang / Journal of Biomedical Informatics 58 (2015) 80–88 85sensitivity (Sn) of these two methods. Since there are few tools or
sever available, we also submit the drugs’ name in SuperPred ser-
ver updated in 2014 [39] (http://prediction.charite.de) to make a
comparison. The predictive accuracy of SuperPred, NetPredATC
and our dD-Hybrid method are compared (Fig. 5). We can see from
it that our method has a better accuracy than NetPredATC on four
subsets and has a better accuracy than SuperPred except on IC
dataset. Take GPCRs for example, SuperPred can predict 215
drug-ATC code pair correctly and its accuracy is 0.716. NetPredATC
can predict 219 drug-ATC code pairs correctly and its accuracy is
0.74 while our dD-Hybrid method can predict 260 drug-ATC code
pairs and its accuracy is 0.867. Further, we provide many evaluat-
ing indexes and a weighted overall score of three methods on four
datasets (Table 3). We can see our method performs better than
other two methods. It also means our dD-Hybrid method can be
a useful tool for further new ATC code prediction for existing drugs.
3.4. Novel predictions
To validate if our method can obtain useful predictions, we
focus on the unlabeled samples. The top five predicted interactionsFig. 5. The predictive accuracy of SuperPred, NetPredATC and our dD-Hybrid
method.
Table 3
Evaluating indexes and weighted overall score of three methods on four data sets.
Datasets Methods Sn Sp F-measure
Enzymes SuperPred 0.899 0.741 0.836
NetPredATC 0.731 0.799 0.764
dD-Hybrid 0.894 0.825 0.864
ICs SuperPred 0.868 0.740 0.816
NetPredATC 0.686 0.797 0.737
dD-Hybrid 0.806 0.794 0.806
GPCRs SuperPred 0.730 0.757 0.739
NetPredATC 0.763 0.796 0.737
dD-Hybrid 0.867 0.797 0.837
NRs SuperPred 0.758 0.734 0.750
NetPredATC 0.726 0.789 0.756
dD-Hybrid 0.886 0.768 0.859
Table 4
The top 5 predicted drug ATC-code pairs by dD-Hybrid method on IC dataset.
KEGG ID (Annotation) Old ATC New ATC (Annotat
D02356 (Verapamil) C08DA01 R05DA04 (Codeine
D04999 (Methylphenidate) N06BA04 R05DA04 (Codeine
D01287 (Levobupivacaine hydrochloride) N01BB10 S01HA07(Lidocaine
D00638 (Flecainide acetate) C01BC04 S01HA02(Oxybupr
D00642 (Quinidine gluconate) C01BA01 A03FA02 (Cisapridon ICs, Enzyme, GPCRs, and NRs datasets are listed in Table 4 and
Tables S1–3 (in the Supplementary material), respectively. Since
the drug and ATC-code annotation in our dataset is the 2013 ver-
sion, there is barely no difference with the edition available now.
Therefore, for each new prediction pairs, we check out their anno-
tation from Drugbank [3] and WHOCC (http://www.whocc.no/atc_
ddd_index/) database.
For IC dataset, we list top five predictions with highest probabil-
ity by combing PFAM information as PFAM information performs
better than the rest two combinations (Table 4). We also find some
connections between drugs with common domains in the sub-
networks extracted from the drug-PFAM network (Fig. 6).
For example, verapamil (KEGG id D02356) is a calcium channel
blocker that is a class IV and anti-arrhythmia agent. It also has
antiarrhythmic activity. It is effective at reducing blood pressure
and treating arrhythmia. So the drug is categorized into C class
in ATC (cardiovascular system). However, researches have shown
that the drug can also treat cluster headache [37]. And its interac-
tion mechanism in cluster headache is thought to be linked to its
calcium-channel blocker effect. Its new predicted ATC code is
R05DA04 (Codeine). It is an opioid analgesic related to morphine,
but with less potent analgesic properties and mild sedative effects.
It also acts centrally to suppress cough. So its annotation is consis-
tent with the drug annotation, which proves its accuracy. It can be
seen that D02356 has common PFAM domain PF00001 with
D00195, D02101 and D03580 (Fig. 6). These three drugs all belong
to the drugs treating respiratory system and their ATC code is
R05DA04. So there is a high probability that it’s a new
classification.
Levobupivacaine hydrochloride (D01287) is a local anesthetic
for the treatment of surgery and obstetrics or regional anesthesia
and postoperative pain. Its original ATC category is N (nervous sys-
tem). The new predicted ATC code is S01HA07 (Lidocaine). It is one
kind of local anesthesia and cardiac depressant. It is mostly used in
cardiac surgery and catheterization or other heart diseases. It is an
exact match for the annotation of the drug. In Fig. 6, D01287 has
common PFAM domains PF00520 and PF06512 with D00358 and
D02086. These two drugs, both belong to the sensory organ systemMCC AUC AUPR ACC Weighted overall score
0.651 0.852 0.787 0.822 0.798
0.546 0.841 0.732 0.765 0.740
0.721 0.898 0.892 0.860 0.851
0.614 0.825 0.787 0.804 0.780
0.563 0.816 0.759 0.740 0.728
0.612 0.863 0.867 0.806 0.793
0.512 0.804 0.745 0.744 0.719
0.534 0.816 0.738 0.741 0.732
0.665 0.878 0.881 0.832 0.822
0.592 0.837 0.822 0.746 0.748
0.527 0.844 0.827 0.757 0.747
0.704 0.884 0.883 0.858 0.835
ion) Drugs with common new ATC Common domains
) D00195 D02101 D03580 PF00001
) D00195 D02101 D03580 PF00001
) D00358 D02086 PF00520 PF06512
ocaine) D00740 D01768 PF00520 PF06512
e) D00274 PF00027 PF00520 PF13426
Fig. 6. Three sub-networks extracted from IC-PFAM network. In the sub-network, drugs in the new predictions and drugs with the same ATC code we already know are all
connected to some common PFAM domains, which verify the assumption that drugs having common domains tend to have the same ATC code.
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fication is convincible.
D00642 (Quinidine gluconate) has three common PFAM
domains PF00027, PF00520 and PF13426 with drug D00274. In
the novel predictions, D00642 has the same ATC code with
D00274. It may suspect that drugs having more common domains
are more likely to have similar ATC code. Also, we find among these
three common PFAM domains, PF00027 and PF00520 are inter-
acted with each other, which is verified in DOMINE [38] database
(connected in red dashed line). It shows that domains connected
with drugs having the same ATC code tend to have interactions
with each other, which is exactly the same as the conclusion in
Wang et al. ’s [15] paper.
For drugs in new predictions and drugs with the same ATC code
above, they have common domains instead of target proteins. So
our method may be a good complement for the method based on
target proteins to predict drug’s ATC code when two drugs don’t
have common target proteins.4. Conclusion and discussion
In this paper, we present a new approach, dD-Hybrid, to predict
drug’s new ATC codes by combing drug–domain information into
integrated features. After integrating drug chemical fingerprint
similarity and ATC evaluating score into drug–drug similarity and
ATC–ATC similarity, we obtain the improved features related to
drug and ATC-code by a feature-combination method. Our main
contribution is that we construct a drug–domain network and
combine it into our prediction. The 10-fold cross-validation tests
show that our method performs better than SuperPred and NetPre-
dATC in accuracy on four benchmark datasets. In addition, we also
compare four conditions combining none domain, CATH, PFAM,
both of CATH and PFAM. We find three conditions combining
domain information have a better result than combing none
domain, which verifies our assumption that drugs connected withcommon domains are likely to have the same ATC codes. More
interestedly, we also find some domains relating to the same ATC
category interact with each other have a high probability of sharing
similar functions.
Further, we find that single similarity feature may not achieve
an ideal result in drug’s ATC prediction as there are many factors
impacting on drugs and ATC codes. The ATC evaluating score sim-
ilarity can be more useful when ATC hierarchical structure similar-
ity is low. Though the similarity-based method may have some
good results, we investigate the biological factors impact on the
interaction between drug and ATC-code. The relationship between
drug and domain may be one important factor of them.
Although drug–domain connections have been used in drug–
target prediction [15] and drug-side effects prediction [18], our
work is the first to predict drug’s ATC-code from a domain level.
Our results support the idea that protein domain with structural
and functional building blocks is an important feature for drug
and ATC prediction. However, there still exist some limitations in
our method. Our dataset only covers a fraction of the drug space
and should extend to be more comprehensive. Besides, the method
can be defective in the condition that drugs have no interacted tar-
get proteins. It may become a problem in practical application. As
demonstrated in a series of recent publications (see, e.g.,
[40,42,44,53–56]) in developing new prediction methods, user-
friendly and publicly accessible web-servers will significantly
enhance their impacts [57], we shall make efforts to provide a
web-server for our method in the future work. With the continu-
ous improvement of these technologies, we believe this proposed
method will offer valuable insights for the identification of novel
ATC codes in a more specific way.Conflict of interest
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